Sanofi Plans Further Consumer Health Divestments As It Reports Slow Start To Year
Executive SummarySanofi tells investors to expect further Consumer Healthcare brand divestments in 2019 as it continues to rationalize its portfolio following the transformational acquisition of Boehringer Ingelheim's OTC business in 2017. As a result of divestments in 2018, as well as a number of seasonal factors, Sanofi reported a 0.6% rise in Consumer Healthcare's sales in Q1.
You may also be interested in...
Sanofi consumer health chief Alan Main says with the US the largest OTC drug market, a successful switch for Tamiflu, marketed in the US by Roche subsidiary Genentech, would support the firm's global strategy for expanding cough and cold remedy sales.